Prostate cancer: significant additional benefit for PSMA diagnostics with gozetotide

15 October 2024 - Because of the direct link between diagnosis and therapy, the data from the early benefit assessment ...

Read more →

Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent

1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...

Read more →